STOCK TITAN

Cel-Sci Corp. - CVM STOCK NEWS

Welcome to our dedicated news page for Cel-Sci (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on Cel-Sci.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cel-Sci's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cel-Sci's position in the market.

Rhea-AI Summary
CEL-SCI Corporation (CVM) reported financial results and key clinical & corporate developments for Multikine® in head and neck cancer patients. Recent data presented at ESMO Congress showed a 73% survival rate with Multikine vs 45% in control, with a 28% absolute survival benefit. Statistically significant results with no safety concerns. Target population identified for regulatory filings, estimated at 145,000 global patients annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
earnings
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) closes a public offering of 3,875,000 shares of common stock at $2.00 per share, raising $7.75 million for continued development of Multikine* and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
offering
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) announces a public offering of 3,875,000 shares of common stock at $2.00 per share, aiming to raise $7.75 million for further development of Multikine and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.68%
Tags
offering
Rhea-AI Summary
CEL-SCI Corporation completes the commissioning of its Multikine manufacturing facility, a key step in preparing for regulatory approval for the treatment of head and neck cancer. The facility has been expanded and upgraded in anticipation of filing a Biologics License Application with the FDA and other regulators. This achievement signifies a significant milestone in bringing Multikine to market, and the company's CEO emphasizes the high value of their manufacturing trade secret, capability, and know-how.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
none
-
Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) has received a product-specific waiver from the European Medicines Agency (EMA) Paediatric Committee, allowing them to commercialize their cancer immunotherapy Multikine in the European Union. This waiver is a significant step forward for the company, as it eliminates a major hurdle in their path towards commercialization in Europe. The waiver ensures that the company does not face delays in their plans for commercialization. The EU Paediatric Regulation, enacted in 2007, aims to strengthen the investigation and development of medicinal products for the pediatric population. This regulatory change has a direct impact on CEL-SCI's ability to bring Multikine to the market in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments. The company identified the target head and neck cancer patient population for Multikine, which saw a 73% survival rate vs 45% in the control at 5 years. The UK's National Institute for Health and Care Excellence (NICE) selected Multikine to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck. Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression. Financially, research and development expenses decreased by 11% and general and administrative expenses decreased by 16%. Net loss narrowed by 12% to approximately $32.2 million for the twelve months ended September 30, 2023 from $36.7 million in fiscal 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
earnings
Rhea-AI Summary
CEL-SCI Corporation (CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the UK. NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.27%
Tags
none
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) Announces Closing of $5 Million Public Offering for Cancer Immunotherapy Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
offering
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) announced the pricing of an offering of 2,490,000 shares of its common stock at $2.00 per share, generating gross proceeds of approximately $5 million. The net proceeds will be used for the development of Multikine, general corporate purposes, and working capital. The offering is expected to close on November 20, 2023. ThinkEquity is the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.57%
Tags
offering
News
Rhea-AI Summary
CEL-SCI Corporation releases a shareholder letter from CEO Geert Kersten, detailing the efficacy of Multikine in head and neck cancer patients and plans for regulatory approval. The letter highlights the well-defined target population, the pre-surgical responses caused by Multikine, and the outstanding survival benefit. CEL-SCI believes they meet the necessary factors for approval and are eager to move forward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.26%
Tags
none
Cel-Sci Corp.

NYSE:CVM

CVM Rankings

CVM Stock Data

110.66M
48.49M
3.15%
12.42%
14.73%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Vienna

About CVM

cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.